TWST News and Press, Twist Bioscience Corporation From 02/03/23

Shares of Twist Bioscience (NASDAQ: TWST) were sinking 17.5% as of 11:18 a.m. ET on Friday. The steep decline came after the synthetic DNA maker announced its fiscal 2023 first-quarter results. Twist reported Q1 revenue of $54.2 million, up 29% year over year. This revenue total narro...

Twist Bioscience Corporation ( NASDAQ: TWST ) lost ~6% pre-market Friday after the maker of synthetic DNA products issued Q1 FY23 results setting its guidance for the second quarter below expectations. Thanks to $49M of combined SynBio revenue and NGS revenue, the company expe...

Twist Bioscience press release ( NASDAQ: TWST ): Q1 GAAP EPS of -$0.74 beats by $0.36 . Revenue of $54.24M (+29.1% Y/Y) misses by $0.23M . Q2 Outlook : Revenue is expected to be approximately $56.5M vs. consensus of $61.83M; Gross margin is expected to be 30%. ...

– Revenue of $54.2M in 1QFY23 increased 29% over $42.0M in 1QFY22 – – Orders increased to $64.7M in 1QFY23, an increase of 30% over 1QFY22 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of hig...

Twist Bioscience ( NASDAQ: TWST ) is scheduled to announce Q1 earnings results on Friday, February 3rd, before market open. The consensus EPS Estimate is -$1.17 (-28.6% Y/Y) and the consensus Revenue Estimate is $54.47M (+29.7% Y/Y). Over the last 2 years, TWST has beaten EP...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - February 1, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

110,000 square-foot state-of-the-art facility supports significantly expanded product manufacturing capacity and will enable new product introductions Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality syntheti...

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022, before the openin...

Summary Let's continue our roundtable series with Growth, Tech and Crypto, and Quantitative, Technical analysis coverage. Nine of our Marketplace contributors give their analysis and share one top idea. We end the series with Biotech and Healthcare coverage. ~ By Ashutosh Go...